Answers are grounded in this paper and cite their sources.
Efficient antitumor immunity requires effective coupling of tumor-antigen generation with dendritic-cell (DC) activation. Here, we developed Ti@EC GM−CSF , a living bacterial biohybrid designed to spatially colocate sonocatalytic nanomaterials with a local source of DC-supportive cytokine and to link ultrasound (US)-triggered tumor injury with time-dependent intratumoral GM-CSF availability. GM-CSF-expressing Escherichia coli BL21(DE3) was decorated with TiO 1+x nanorods, integrating bacterial cytokine production and US-responsive reactive oxygen species generation within a single platform. US-activated Ti@EC GM−CSF induced immunogenic tumor-cell injury and increased the proportion of CD80 + CD86 + bone marrow-derived DCs in vitro. In CT26 tumor-bearing mice, the treatment increased intratumoral GM-CSF availability, greater abundance of CD11c + CD103 + cells, and increased frequencies of mature DCs and CD3 + CD8 + T cells. Dual-fluorescence imaging further revealed spatial colocalization of bacterial and inorganic component signals in tumors at the examined time points. Moreover, combining Ti@EC GM−CSF with anti-PD-L1 treatment resulted in the greatest reduction in primary and untreated contralateral tumor burden among the tested groups in a bilateral CT26 tumor model. Together, these findings support a spatiotemporal design strategy that integrates acute sonocatalytic tumor injury with local GM-CSF-associated immune support. Although the causal sequence and the relative contributions of individual components remain to be fully established, this platform provides a promising approach for linking local tumor treatment with DC-centered antitumor immunity.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: